India's top drugmaker by revenue Sun Pharma on Monday launched its anti-baldness drug Leqselvi in the U.S., following the ...

LEQSELVI has been approved by the US FDA, following strong results from clinical trials and is now available to adults ...

Shares of Sun Pharma rose 2 percent to Rs 1,711 in morning trade on July 15, extending their gains for a third straight ...

"The launch of LEQSELVI in the U.S. brings an effective, new treatment option for severe alopecia areata to eligible patients and the healthcare providers who treat them," said Richard Ascroft, CEO, ...

Sun Pharma will pay Incyte an upfront fee and royalties to market Leqselvi in the US for alopecia areata until patent expiry ...

Indian drugmaker Sun Pharmaceutical Industries together with its subsidiaries announced that further to its intimation dated ...

The delay in Sun Pharma's launch of Leqselvi in the US was caused by a patent infringement case, which was later settled in a ...

Sun Pharmaceutical Industries has reached a settlement agreement with Incyte Corporation concerning Leqselvi, a drug for ...

Sun Pharma shares surged after a settlement with Incyte over Leqselvi, a drug for severe hair loss. The agreement includes a ...

Sun recieved approval from the US Food and Drug Administration for Leqselvi in July 2024. Soon after the regulator’s approval ...

Sun Pharma settles litigation with Incyte over Leqselvi, launches product for severe alopecia areata treatment in the US.

Sun Pharma settles litigation with Incyte, gains license for alopecia treatment, launches LEQSELVI tablet in the US.